Novel glucagon receptor antagonist peptides improve glycaemic control and partially protect against streptozotocin induced diabetes in mice

2015 ◽  
Author(s):  
Finbarr O'Harte ◽  
Laura McShane ◽  
Nigel Irwin
Keyword(s):  
Glycaemic Control ◽  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Diabetes In Mice ◽  
Antagonist Peptides ◽  
Glucagon Receptor Antagonist ◽  
Streptozotocin Induced Diabetes

Stability and efficacy studies in N-terminally truncated glucagon receptor antagonist peptides

2010 ◽  
Vol 164 (1) ◽  
pp. 41-42
Author(s):  
E.P. Rafferty ◽  
Z. Franklin ◽  
N. Irwin ◽  
F.P.M. O'Harte
Keyword(s):  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Antagonist Peptides ◽  
Glucagon Receptor Antagonist ◽  
Efficacy Studies

An Allosteric Glucagon Receptor Antagonist, LGD-6972, Displays Biased Receptor Signaling

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1117-P ◽  
Author(s):  
ERIC G. VAJDA ◽  
LIN ZHI ◽  
KEITH MARSCHKE
Keyword(s):  
Receptor Antagonist ◽  
Receptor Signaling ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

scholarly journals Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

2017 ◽  
Vol 19 (11) ◽  
pp. 1521-1528 ◽  
Author(s):  
Cristina B. Guzman ◽  
Xiaotian M. Zhang ◽  
Rong Liu ◽  
Arie Regev ◽  
Sudha Shankar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Liver Fat ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽  
2018 ◽  
Vol 62 (2) ◽  
pp. 371-380 ◽  
Author(s):  
Barry Gumbiner ◽  
Brooke Esteves ◽  
Vanessa Dell ◽  
Tenshang Joh ◽  
Pamela D. Garzone ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Controlled Trial ◽  
Phase 1 ◽  
Double Blind ◽  
Glucagon Receptor ◽  
Double Blind Placebo ◽  
Dose Study ◽  
Glucagon Receptor Antagonist

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

2017 ◽  
Vol 19 (8) ◽  
pp. 1071-1077 ◽  
Author(s):  
Christof M. Kazda ◽  
Juan Frias ◽  
Irene Foga ◽  
Xuewei Cui ◽  
Cristina B. Guzman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Ambulatory Blood Pressure ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document